Skaarup SH, Schmid JM, Skjold T, et al. - This 3-year follow-up double-blind randomized placebo-controlled trial was conducted on patients (n = 36) with grass pollen rhinoconjunctivitis to determine the impact of intralymphatic allergen immunotherapy (ILIT). The patients received treatment with 3 ILIT injections and an ILIT booster 1 year later, 3 ILIT injections and a placebo booster, or 3 placebo injections and a placebo booster. Improvement in a combined symptom and medication score (cSMS) was the primary outcome. Experts created a new assessment tool with a linear regression model of cSMS and grass pollen counts. Findings demonstrated that grass pollen allergy symptoms and use of rescue medication were substantially decreased by ILIT, significantly in the first season post-treatment. No additional impact of a booster injection was evident.